Objectives To evaluate the efficacy and tolerability of strontium ranelate in patients with gonarthrosis
Methods 40 patients with a documented diagnosis of gonarthrosis: women - 32 (80%), men - 8 (20%), mean age - 57.4 years (range 49 to 72 years). Comorbidities: hypertension - 24 (60%), ischemic heart disease - in 6 (15%), chronic gastro - 18 (45%). At the time of inclusion, all patients had severe pain: VAS 61,2±10,9 mm,WOMAC - 42,9±12,4, synovitis of the knee joints were recorded in 16 (40%) patients. All (100%) patients received analgetics and NSAIDs. Patients were divided into two groups matched for the main parameters: age, sex, pain intensity, duration of the disease, received therapy. The first group of patients (n=20) was appointed as strontium ranelate at a dose 2 g per day in daily intake, the second group of 20 people received chondroitin sulfate 1 g per day. Efficacy was assessed in terms of the joint syndrome, WOMAC index after 3 months of therapy.
Results After 3 months of treatment with strontium ranelate patients showed a significant (p<0.05) reduction in pain during movement (VAS 23,2±7,2 mm), joint tenderness to palpation (VAS =21,2±9,2 mm), index WOMAC (24,3±9,0). Dynamics of pain was significantly lower in the group of patients receiving chondroitin sulfate. The effect of treatment was evaluated as good (pain reduction of 50% or more) in 12 (60%) of patients receiving storntium ranelate and in 10 (50%) - the control group, satisfactory (pain reduction of 20-50%) 7 (35%) and eight (40%), no effect in 1 (5%) and 2 (10%) patients. Secondary synovitis completely reduced in all patients. After 1 month of treatment 10 patients (50%) of each group did not need NSAIDs, 40% (8) in the base and 7 (35%) of control group reduced by 50% of the original dose, and 2 (10%) of first and 3 (15%) patients of the second group - continued to take NSAIDs in the same dosage. No serious adverse effects, worsening of comorbidities were registered.
Conclusions By observing the results, strontium ranelate has a pronounced analgesic effect, which is more than the effect of several standard conventional therapies and may be caused by the influence on the subchondral bone. Strontium ranelate is safe in the treatment of knee osteoarthritis.
Disclosure of Interest None declared